Your Subtitle text
The corps of drug discovery

We have deep expertise in the synthesis, analysis, and early stage development of adenosine receptor-based compounds, with a focus on A2A and A2B antagonists, and A2A agonists. Our proprietary compounds are highly potent and selective, and – most importantly, have molecular properties that enable enhanced distribution in tissue and penetration of human skin – and the opportunity for novel therapies that could address a broad range of large, chronic, underserved diseases:

A2A/A2B antagonists for a range of tumors, as a mono- or combination therapy, including:

  • Solid tumors, e.g., breast, colorectal, melanoma, lung, prostate, bladder

  • Hematological malignancies, e.g., multiple myelomas, acute lymphocyte leukemia

An A2A agonist patch or cream/gel for auto-inflammatory/autoimmune diseases, such as:

  • Rheumatoid Arthritis/psoriasis

  • Crohn's Disease/ulcerative colitis

  • Diabetic nephropathy

  • Sickle-Cell Disease

  • Immune system disorders, e.g., Graft-vs.-Host-Disease

  • Diabetic foot ulcers/hard-to-heal wounds

  • Bacterial infections, e.g., Clostridium Difficile, Sepsis

Oral A2B antagonists, with the potential to address:

  • Asthma

  • Type 2 diabetes

  • Atherosclerosis

And unique A2A agonists for specialty indications:

  • Stress imaging – a highly selective compound with the potential to significantly reduce side effects versus currently marketed products

  • Glaucoma –a highly potent, hydrophobic compound as ophthalmic drops

  • Local pain –a compound with very good skin penetration for a lower back pain patch, and a cream/gel for hand, elbow and knee arthritis pain and inflammation

Our focus is on developing druggable products with the potential for accelerated pathways to market. We take steps to de-risk our compounds for each indication by performing early critical non-clinical screening studies to identify lead compounds with the highest probability of success. We are efficient with resources and have made significant progress in our first three years.